Patients Can Now Use Site to Consult with Qualified Health Care Professionals On-Demand, Order and Potentially Receive Dermatologist-Recommended Skin Care Products
BRIDGEWATER, N.J., Feb. 18, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the launch of a new telemedicine platform on Dermatology.com, the first and only non-reimbursed, cash-pay prescription program in dermatology in the United States. The enhanced website will offer patients the ability to consult with a health care professional, order and potentially receive a prescription on-demand for many of the branded dermatology products available in the program.1 Some products, such as SOLODYN® (minocycline hydrochloride) extended release tablets, EFUDEX® (fluorouracil) topical cream, 5%, and ALDARA® (imiquimod) cream, 5%, which are for more serious skin conditions, will require an in-office visit instead.
"At Ortho Dermatologics, we understand that patients with certain skin conditions, particularly acne and fine lines and wrinkles, can face multiple barriers to getting the skin care treatments they need," said Bill Humphries, president, Ortho Dermatologics. "By providing an on-demand solution where patients can conveniently consult with a medical professional online, order our clinically proven medicines directly, and receive prompt delivery, we believe we can deliver the best possible experience and access for patients."
To use the new telemedicine service1 on Dermatology.com, patients are required to submit a photo of their skin-related need and other information on their health, medical history and lifestyle via their mobile device or desktop. Once the submission is placed, which takes approximately three minutes, the patient will receive an email confirmation stating that their submission is being reviewed by a health care provider. Typically within 24 hours, the health care provider will either provide the patient with a prescription for one of the company's branded prescription products available on the site, based on the assessment by the health care provider, or recommend the patient visit a board-certified dermatologist if the skin condition warrants an in-person consultation. To help these patients connect directly to a board-certified dermatologist, the site will feature a direct link to the American Academy of Dermatology Association's Find a Dermatologist locator.2
Through Dermatology.com, patients have direct access to many of Ortho Dermatologics' proven, high-quality, branded dermatology medicines. The products available on the site include some of the company's iconic brands, including Retin-A® (tretinoin) cream as well as newer products such as ALTRENO® (tretinoin) Lotion, 0.05%. The company also recently added four more products to the program, SOLODYN® (minocycline hydrochloride) extended release tablets, RENOVA® (tretinoin cream 0.02%), LOPROX® shampoo (ciclopirox 1%), and BenzEFoam® (benzoyl peroxide emollient foam 5.3%/9.8%), bringing the total product count to 15. The addition of BenzEFoam 5.3% also marks the site's first over-the-counter option for patients.
Since its launch in March 2019, Dermatology.com has helped thousands of patients get access to branded dermatology products at transparent prices through participating pharmacies, including all Walgreens U.S. retail pharmacies.
About Ortho Dermatologics Ortho Dermatologics is one of the largest prescription and aesthetic dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Ortho Dermatologics portfolio also includes several leading medical device systems for aesthetic applications, such as skin tightening and resurfacing, laser hair removal and preventative therapeutic skin care treatments. More information can be found at www.ortho-dermatologics.com.
About Bausch Health Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of Bausch Health management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in Bausch Health's most recent annual or quarterly report and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
1Where available by law 2 Expected to be available on the site in March 2020